Negative Impact of Sigma-1 Receptor Agonist Treatment on Tissue Integrity and Motor Function Following Spinal Cord Injury.

PRE-084 gliosis motor function neuromuscular junction sigma 1 receptor spinal cord injury

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 07 10 2020
accepted: 14 01 2021
entrez: 1 3 2021
pubmed: 2 3 2021
medline: 2 3 2021
Statut: epublish

Résumé

In traumatic spinal cord injury, the initial trauma is followed by a cascade of impairments, including excitotoxicity and calcium overload, which ultimately induces secondary damages. The sigma-1 receptor is widely expressed in the central nervous system and is acknowledged to play a key role in calcium homeostasis. Treatments with agonists of the sigma-1 receptor induce beneficial effects in several animal models of neurological diseases. In traumatic injury the use of an antagonist of the sigma-1 receptor reversed several symptoms of central neuropathic pain. Here, we investigated whether sigma-1 receptor activation with PRE-084 is beneficial or detrimental following SCI in mice. First, we report that PRE-084 treatment after injury does not improve motor function recovery. Second, using

Identifiants

pubmed: 33643047
doi: 10.3389/fphar.2021.614949
pii: 614949
pmc: PMC7902910
doi:

Types de publication

Journal Article

Langues

eng

Pagination

614949

Informations de copyright

Copyright © 2021 Lattard, Poulen, Bartolami, Gerber and Perrin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Pharmacol. 2019 Mar 22;10:222
pubmed: 30967775
J Histochem Cytochem. 1964 Mar;12:219-21
pubmed: 14187330
Glia. 2009 May;57(7):744-54
pubmed: 19031439
Handb Exp Pharmacol. 2017;244:81-108
pubmed: 28275911
Front Aging Neurosci. 2017 Jul 19;9:230
pubmed: 28769787
Neuroscience. 2009 Aug 4;162(1):31-8
pubmed: 19345724
Spinal Cord. 2006 Mar;44(3):182-7
pubmed: 16130019
Curr Neuropharmacol. 2018;16(1):97-116
pubmed: 28554311
Int J Biochem Cell Biol. 2020 Sep;126:105803
pubmed: 32668330
J Neurotrauma. 2018 Dec 15;35(24):2924-2940
pubmed: 29877129
Neurotox Res. 2019 Jan;35(1):1-18
pubmed: 29127580
Cell. 2007 Nov 2;131(3):596-610
pubmed: 17981125
World Neurosurg. 2018 May;113:e345-e363
pubmed: 29454115
Sci Rep. 2018 Mar 1;8(1):3873
pubmed: 29497125
CNS Neurosci Ther. 2013 Sep;19(9):705-13
pubmed: 23745740

Auteurs

Alise Lattard (A)

MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.

Gaëtan Poulen (G)

MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Department of Neurosurgery, CHU, Montpellier, France.

Sylvain Bartolami (S)

MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.

Yannick N Gerber (YN)

MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.

Florence E Perrin (FE)

MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Institut Universitaire de France (IUF), University of Montpellier, INSERM U1198, Montpellier, France.

Classifications MeSH